[1]刘文玲,朱明明,马德花.miR-125b在多发性骨髓瘤中的表达及与预后的关系[J].医学信息,2023,36(21):61-65.[doi:10.3969/j.issn.1006-1959.2023.21.013]
　LIU Wen-ling,ZHU Ming-ming,MA De-hua.Expression of miR-125b in Multiple Myeloma and its Relationship with Prognosis[J].Journal of Medical Information,2023,36(21):61-65.[doi:10.3969/j.issn.1006-1959.2023.21.013]
点击复制

miR-125b在多发性骨髓瘤中的表达及与预后的关系()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年21期
页码:
61-65
栏目:
论著
出版日期:
2023-11-01

文章信息/Info

Title:
Expression of miR-125b in Multiple Myeloma and its Relationship with Prognosis
文章编号:
1006-1959（2023）21-0061-05
作者:
刘文玲; 朱明明; 马德花
（青海大学附属医院血液科，青海 西宁 810001）
Author(s):
LIU Wen-ling; ZHU Ming-ming; MA De-hua
(Department of Hematology,Affiliated Hospital of Qinghai University,Xining 810001,Qinghai,China)
关键词:
多发性骨髓瘤; miR-125b; 预后
Keywords:
Multiple myeloma; miR-125b; Prognosis
分类号:
R733.3
DOI:
10.3969/j.issn.1006-1959.2023.21.013
文献标志码:
A
摘要:
目的 探讨miR-125b在多发性骨髓瘤（MM）患者外周血中的表达及与预后的关系。方法 选择青海大学附属医院血液科2020年6月-2021年8月收治的25例初诊MM患者设为初诊组，治疗后（VRD方案化疗4周期）MM疗效评价达CR（IMWG疗效评价标准）的患者20例设为完全缓解组，另选取健康者15例设为对照组。比较三组实验室指标，应用Pearson相关性分析初诊MM患者血清miR-125b表达水平与临床参数的关系。应用多因素Logistic回归分析初诊MM患者预后影响因素。应用ROC曲线分析miR-125b单独及联合检测对初诊MM患者预后的预测价值。结果 初诊组miR-125b表达、白蛋白水平低于完全缓解组和对照组，球蛋白、乳酸脱氢酶、β2微球蛋白高于完全缓解组和对照组，差异有统计学意义（P＜0.05）；而完全缓解组与对照组miR-125b表达、球蛋白、乳酸脱氢酶、β2微球蛋白、白蛋白水平比较，差异无统计学意义（P＞0.05）；且三组血红蛋白、肌酐水平比较，差异无统计学意义（P＞0.05）。不同ISS分期级有无遗传学突变中miR-125b表达比较，差异有统计学意义（P＜0.05）；而不同年龄、性别、M蛋白类型中miR-125b表达比较，差异无统计学意义（P＞0.05）。Pearson相关性分析显示，初诊MM患者miR-125b表达量与M蛋白、球蛋白含量、ISS分期呈负相关，而与乳酸脱氢酶、β2微球蛋白、白蛋白、血红蛋白、肌酐、遗传学突变均无相关性（P＞0.05）。Logistic回归分析，结果显示M蛋白、球蛋白及miR-125b表达水平为患者预后不佳的危险因素。ROC曲线分析显示，miR-125b联合M蛋白、球蛋白的预后预测效能优于单独检测。结论 miR-125b在初诊MM患者血清中表达下调，分期越晚表达量越低，联合M蛋白及球蛋白检测对MM患者预后有一定预测价值。
Abstract:
Objective To investigate the expression of miR-125 b in peripheral blood of patients with multiple myeloma (MM) and its relationship with prognosis.Methods Twenty-five patients with initial diagnosis of MM who were admitted to the Department of Hematology of the Affiliated Hospital of Qinghai University between June 2020 and August 2021 were selected as the primary diagnosis group, twenty patients whose MM efficacy evaluation reached CR (IMWG efficacy evaluation standard) after treatment (4 cycles of chemotherapy with VRD regimen) were set up as the complete remission group, and another fifteen healthy people were selected as the control group. The laboratory indexes of the three groups were compared, and the relationship between serum miR-125 b expression level and clinical parameters in newly diagnosed MM patients was analyzed by Pearson correlation. Multivariate Logistic regression analysis was used to analyze the prognostic factors of newly diagnosed MM patients. ROC curve was used to analyze the predictive value of miR-125b alone and combined detection on the prognosis of newly diagnosed MM patients.Results The expression of miR-125b and albumin level in the newly diagnosed group were lower than those in the complete remission group and the control group, and the globulin, lactate dehydrogenase and β2 microglobulin were higher than those in the complete remission group and the control group, the differences were statistically significant (P<0.05); whereas, There was no significant difference in the expression of miR-125b, globulin, lactate dehydrogenase, β2 microglobulin and albumin between the complete remission group and the control group (P>0.05), and there was no significant difference in hemoglobin and creatinine levels among the three groups (P>0.05). There was a statistically significant difference in the expression of miR-125b in different ISS stages and with or without genetic mutations (P<0.05). There was no significant difference in the expression of miR-125 b in different ages, genders and M protein types (P>0.05). Pearson correlation analysis showed that the expression of miR-125b in newly diagnosed MM patients was negatively correlated with M protein, globulin content and ISS stage, but not with lactate dehydrogenase, β2 microglobulin, albumin, hemoglobin, creatinine and genetic mutations (P>0.05). Logistic regression analysis showed that the expression levels of M protein, globulin and miR-125 b were risk factors for poor prognosis of patients. ROC curve analysis showed that the prognostic predictive efficacy of miR-125b combined with M protein and globulin was better than that of single detection.Conclusion The expression of miR-125b is down-regulated in the serum of newly diagnosed MM patients, and the later the stage is, the lower the expression is. The combined detection of M protein and globulin has certain predictive value for the prognosis of MM patients.

参考文献/References:

[1]Cowan AJ,Green DJ,Kwok M,et al.Diagnosis and Management of Multiple Myeloma: A Review[J].JAMA,2022,327(5):464-477.[2]Wallington-Beddoe CT,Mynott RL.Prognostic and predictive biomarker developments in multiple myeloma[J].J Hematol Oncol,2021,14(1):151. [3]van de Donk NWCJ,Pawlyn C,YongKL.Multiple myeloma[J].Lancet,2021,397(10272):410-427.[4]Jung SH,Lee SE,Lee M,et al.Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma[J].Haematologica,2017,102(11):456-459.[5]Varga C,Maglio M,Ghobrial IM,et al.Current use of monoclonal antibodies in the treatment of multiple myeloma[J].Br J Haematol,2018,181:447-459.[6]Peng B,Theng PY,Le MTN.Essential functions of miR-125b in cancer[J].Cell Prolif,2021,54(2):e12913.[7]Shi Y,Liu Z,Lin Q,et al.MiRNAs and Cancer: Key Link in Diagnosis and Therapy[J].Genes(Basel),2021,12(8):1289.[8]Li Z,Liu L,Du C,et al.Therapeutic effects of oligo-single-stranded DNA mimicking of hsa-miR-15a-5p on multiple myeloma[J].Cancer Gene Ther,2020,27(12):869-877.[9]Lu Y,Wu D,Wang J,et al.miR-320a regulates cell proliferation and apoptosis in multiple myeloma by targeting pre-B-cell leukemia transcription factor 3[J].Biochemical and Biophysical Research Communications,2016,473(4):1315-1320.[10]Matuszyk J,Klopotowska D.miR-125b lowers sensitivity to apoptosis following mitotic arrest: Implications for breast cancer therapy[J].J Cell Physiol,2020,235(10):6335-6344.[11]Pula A,Robak P,Robak T.MicroRNA in Multiple Myeloma-A Role in Pathogenesis and Prognostic Significance[J].Curr Med Chem,2021,28(33):6753-6772.[12]Martin T,Huff CA.Multiple myeloma:Current advances and future directions[J].Clin Lymphoma Myeloma Leuk,2019,19:255-263.[13]Misiewicz-Krzeminska I,Krzeminski P,Corchete LA,et al.Factors Regulating microRNA Expression and Function in Multiple Myeloma[J].Non-coding RNA,2019,5(9):1-20.[14]Gao D,Xiao Z,Li HP,et al.The mechanism study of miR-125b in occurrence and progression of multiple myeloma[J].Cancer Med,2018,7(1):134-145.[15]Jiang Y,Ding J,Li J,et al.Effects of microRNA125b on multiple myeloma cell growth in vitro and in vivo[J].Oncol Rep,2018,40(5):2864-2875.[16]Wang JK,Wang Z,Li GD.MicroRNA-125 in immunity and cancer[J].Cancer Lett,2019,10(454):134-145.[17]Morelli E,Leone E,Cantafio ME,et al.Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo[J].Leukemia,2015,29:2173-2183.[18]Chen D,Yang X,Liu M,et al.Roles of miRNA dysregulation in the pathogenesis of multiple myeloma[J].Cancer Gene Ther,2021,28(12):1256-1268.[19]Murray MY,Rushworth SA,Zaitseva L,et al.Attenuation of dexamethasone induced cell death in multiple myeloma is mediated by miR-125b expression[J].Cell Cycle,2013,12:2144-2153.[20]Abdi J,Rastgoo N,Li L,et al.Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis[J].J Hematol Oncol,2017,10(1):169.

相似文献/References:

[1]贾海英,黄睿,王玲玲,等.多发性骨髓瘤患者淋巴细胞亚群变化对免疫功能的影响研究[J].医学信息,2018,31(01):147.[doi:10.3969/j.issn.1006-1959.2018.01.057]
　JIA Hai-ying,HUANG Rui,WANG Ling-ling,et al.The Effect of Lymphocyte Subgroup Changes on Immune Function in Patients with Multiple Myeloma[J].Journal of Medical Information,2018,31(21):147.[doi:10.3969/j.issn.1006-1959.2018.01.057]
[2]黄珍艳.实验室指标对多发性骨髓瘤的诊断价值分析[J].医学信息,2018,31(05):155.[doi:10.3969/j.issn.1006-1959.2018.05.056]
　HUANG Zhen-yan.Diagnostic Value of Laboratory Markers for Multiple Myeloma[J].Journal of Medical Information,2018,31(21):155.[doi:10.3969/j.issn.1006-1959.2018.05.056]
[3]冯江芳.多发性骨髓瘤患者校正血钙的临床分析[J].医学信息,2018,31(10):87.[doi:10.3969/j.issn.1006-1959.2018.10.026]
　FENG Jiang-fang.Clinical Analysis of Corrected Serum Calcium in Patients with Multiple Myeloma[J].Journal of Medical Information,2018,31(21):87.[doi:10.3969/j.issn.1006-1959.2018.10.026]
[4]NEELAM SAH,聂小凤,张 琴,等.宫颈脱落细胞miR-125b与宫颈病变关系及其在HR-HPV 阳性患者分层筛查中的作用研究[J].医学信息,2018,31(23):76.[doi:10.3969/j.issn.1006-1959.2018.23.021]
　NEELAM SAH,NIE Xiao-feng,ZHANG Qin,et al.The Relationship between Cervical Exfoliated Cell miR-125b and Cervical Lesions and its Role in Stratified Screening of HR-HPV Positive Patients[J].Journal of Medical Information,2018,31(21):76.[doi:10.3969/j.issn.1006-1959.2018.23.021]
[5]王晓雪,王芝涛,秦 慧.血小板与淋巴细胞比值在多发性骨髓瘤预后中的价值[J].医学信息,2022,35(12):109.[doi:10.3969/j.issn.1006-1959.2022.12.026]
　WANG Xiao-xue,WANG Zhi-tao,QIN Hui.Prognostic Value of Platelet to Lymphocyte Ratio in Multiple Myeloma[J].Journal of Medical Information,2022,35(21):109.[doi:10.3969/j.issn.1006-1959.2022.12.026]
[6]王 然,孙言非.血清免疫固定电泳、血清蛋白电泳及免疫球蛋白定量对 多发性骨髓瘤的临床诊断价值[J].医学信息,2019,32(11):173.[doi:10.3969/j.issn.1006-1959.2019.11.054]
　WANG Ran,SUN Yan-fei.Clinical Diagnostic Value of Serum Immunofixation Electrophoresis,Serum Protein Electrophoresis and Immunoglobulin Quantification for Multiple Myeloma[J].Journal of Medical Information,2019,32(21):173.[doi:10.3969/j.issn.1006-1959.2019.11.054]
[7]金 英.硼替佐米治疗老年多发性骨髓瘤的效果[J].医学信息,2020,33(06):146.[doi:10.3969/j.issn.1006-1959.2020.06.047]
　JIN Ying.Effect of Bortezomib in the Treatment of Elderly Multiple Myeloma[J].Journal of Medical Information,2020,33(21):146.[doi:10.3969/j.issn.1006-1959.2020.06.047]
[8]燕法红,邱志远,李乾鹏,等.激活蛋白-1家族JunB、c-Jun、c-Maf、c-Fos在多发性骨髓瘤中的表达[J].医学信息,2021,34(23):44.[doi:10.3969/j.issn.1006-1959.2021.23.012]
　YAN Fa-hong,QIU Zhi-yuan,LI Qian-peng,et al.Expression of Activator Protein-1 Family JunB,c-Jun,c-Maf,c-Fos in Multiple Myeloma[J].Journal of Medical Information,2021,34(21):44.[doi:10.3969/j.issn.1006-1959.2021.23.012]
[9]张少晗,应燕萍,赵慧函,等.1990-2019年我国多发性骨髓瘤疾病负担及其变化趋势分析[J].医学信息,2022,35(22):23.[doi:10.3969/j.issn.1006-1959.2022.22.004]
　ZHANG Shao-han,YING Yan-ping,ZHAO Hui-han,et al.Analysis of the Burden of Multiple Myeloma and its Changing Trend in China from 1990 to 2019[J].Journal of Medical Information,2022,35(21):23.[doi:10.3969/j.issn.1006-1959.2022.22.004]
[10]覃泽东,夏玉梅,陈 莉,等.多发性骨髓瘤合并颅内浆细胞瘤的临床及影像学特点分析[J].医学信息,2021,34(05):111.[doi:10.3969/j.issn.1006-1959.2021.05.031]
　QIN Ze-dong,XIA Yu-mei,CHEN Li,et al.Analysis of Clinical and Imaging Characteristics of Multiple Myeloma Combined with Intracranial Plasmacytoma[J].Journal of Medical Information,2021,34(21):111.[doi:10.3969/j.issn.1006-1959.2021.05.031]

更新日期/Last Update: 1900-01-01